Vitamin C with chemotherapy for certain relapsed blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests whether intravenous vitamin C (ascorbic acid) added to chemotherapy can improve outcomes for people with certain relapsed or treatment-resistant lymphomas or chronic myelomonocytic leukemia (CMML). It may help by boosting chemotherapy’s effectiveness and/or changing how the cancer responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have relapsed or refractory lymphoma (or specific CMML/CCUS groups, depending on the study arm) proven by tests/biopsy
- You must have measurable or assessable cancer you can track by scans or biopsy
- Your body-blood counts and organ function must meet specific lab thresholds (blood, liver, kidneys)
- You must be able to get study treatment that uses a central line (PICC or PORT) and attend follow-up visits
- You must be willing to give required blood and tissue samples for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
This Phase 2 study tests a treatment sequence for people with high-risk diffuse large B-cell lymphoma (DLBCL) that includes loncastuximab plus rituximab, then DA-EPOCH-R. It aims to improve responses in patients whose lymphoma has specific high-risk features.
This trial tests if adding high-dose vitamin C (ascorbate) to a standard combination of azacitidine and venetoclax can help adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. It aims to see if this combination is safe and effective.
This trial tests whether adding high-dose vitamin C (ascorbate) to a standard chemotherapy drug (azacitidine) helps people with higher-risk myelodysplastic syndrome (MDS). It is for those who have had little or no prior treatment for MDS.
This trial tests a special high-dose vitamin C infusion, given based on how your body processes it, for people with advanced solid tumors. It aims to see if this vitamin C therapy can be safely combined with your current or new chemotherapy to help control the cancer.
This trial tests whether high doses of vitamin C, given with standard chemotherapy, can help people with multiple myeloma or related plasma cell disorders who have already tried several treatments. It includes a stem cell transplant step, so you must have stored stem cells.
Hear when a new Clonal Cytopenia of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.